Genetic characteristics according to the WHO classification category AML with MDS-related cytogenetic abnormalities and MK (n = 1058)
| Characteristics/cytogenetic abnormalities . | Other, n (%), n = 501 . | MK+, n (%), n = 54 . | MDS+, n (%), n = 238 . | MK+MDS+, n (%), n = 265 . | P . |
|---|---|---|---|---|---|
| t(9;11) | 55 (11) | – | – | – | † |
| t(v;11)(v;q23)* | 52 (10) | 6 (11) | 2 (1) | 1 | < .0001 |
| t(6;9)* | 16 (3) | 3 (6) | – | – | † |
| inv(3) or t(3;3) | 11 (2) | 34 (63) | – | – | † |
| −5 or 5q− | 8 (2) | 5 (9) | 53 (22) | 169 (64) | < .0001 |
| −7 | 36 (67) | 42 (18) | 106 (40) | < .0001 | |
| 7q− | 14 (3) | 5 (9) | 40 (17) | 49 (18) | < .0001 |
| +8 or +8q | 157 (31) | 3 (6) | 48 (20) | 42 (16) | < .0001 |
| +11 or +11q | 23 (5) | 0 | 14 (6) | 20 (8) | < .0001 |
| abnl(12p) | 18 (4) | 4 (7) | 27 (11) | 73 (28) | < .0001 |
| +13 or +13q | 21 (4) | 0 | 12 (5) | 10 (4) | .44 |
| abnl(17p) | 6 (1) | 6 (11) | 12 (5) | 124 (47) | < .0001 |
| −18 or 18q− | 1 (0.2) | 5 (9) | 2 (1) | 56 (21) | < .0001 |
| −20 or 20q− | 23 (5) | 4 (7) | 9 (4) | 57 (22) | < .0001 |
| +21 or +21q | 28 (6) | 0 | 21 (9) | 23 (9) | < .0001 |
| +22 or +22q | 4 (1) | 0 | 14 (6) | 13 (5) | < .0001 |
| Characteristics/cytogenetic abnormalities . | Other, n (%), n = 501 . | MK+, n (%), n = 54 . | MDS+, n (%), n = 238 . | MK+MDS+, n (%), n = 265 . | P . |
|---|---|---|---|---|---|
| t(9;11) | 55 (11) | – | – | – | † |
| t(v;11)(v;q23)* | 52 (10) | 6 (11) | 2 (1) | 1 | < .0001 |
| t(6;9)* | 16 (3) | 3 (6) | – | – | † |
| inv(3) or t(3;3) | 11 (2) | 34 (63) | – | – | † |
| −5 or 5q− | 8 (2) | 5 (9) | 53 (22) | 169 (64) | < .0001 |
| −7 | 36 (67) | 42 (18) | 106 (40) | < .0001 | |
| 7q− | 14 (3) | 5 (9) | 40 (17) | 49 (18) | < .0001 |
| +8 or +8q | 157 (31) | 3 (6) | 48 (20) | 42 (16) | < .0001 |
| +11 or +11q | 23 (5) | 0 | 14 (6) | 20 (8) | < .0001 |
| abnl(12p) | 18 (4) | 4 (7) | 27 (11) | 73 (28) | < .0001 |
| +13 or +13q | 21 (4) | 0 | 12 (5) | 10 (4) | .44 |
| abnl(17p) | 6 (1) | 6 (11) | 12 (5) | 124 (47) | < .0001 |
| −18 or 18q− | 1 (0.2) | 5 (9) | 2 (1) | 56 (21) | < .0001 |
| −20 or 20q− | 23 (5) | 4 (7) | 9 (4) | 57 (22) | < .0001 |
| +21 or +21q | 28 (6) | 0 | 21 (9) | 23 (9) | < .0001 |
| +22 or +22q | 4 (1) | 0 | 14 (6) | 13 (5) | < .0001 |
AML indicates acute myeloid leukemia; MDS, myelodysplasia-related cytogenetic abnormalities according to Swerdlow et al3 ; MK, monosomal karyotype; WHO, World Health Organization; and –, not applicable. Percentages may not add to 100 because of rounding.
One case exhibited a t(6;9) and t(v;11)(v;q23) concurrently.
Per definition no MDS-related changes possible according to Swerdlow et al3 and Döhner et al.6